Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms

被引:0
|
作者
Yakirevich, E
Sabo, E
Lavie, O
Mazareb, S
Spagnoli, GC
Resnick, MB
机构
[1] Technion Univ, Carmel Med Ctr, Dept Pathol, IL-34362 Haifa, Israel
[2] Technion Univ, Rappaport Fac Med, IL-34362 Haifa, Israel
[3] Technion Univ, Carmel Med Ctr, Div Gynecol Oncol, IL-34362 Haifa, Israel
[4] Univ Basel Hosp, Dept Surg, Div Res, CH-4031 Basel, Switzerland
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms and is silent in normal tissues, except for the testis. Expression of two members of this family, MAGE-A4 and NY-ESO-1, has been described in melanomas, germ cell tumors, certain carcinomas and sarcomas, and more recently in uterine neoplasms. The objective of this study was to evaluate the extent and prognostic significance of CT antigen expression in ovarian serous neoplasms. Experimental Design: Seventy-four patients with ovarian neoplasms, including 10 with serous cystadenomas, 11 with serous tumors of borderline malignancy, and 53 with serous carcinomas, were studied. Immunohistochemistry was performed with the 57B monoclonal antibody, which recognizes predominantly the MAGE-A4 antigen and the D8.38 antibody that recognizes NY-ESO-1. Results: MAGE-A4 expression was found to be present in 57% of the serous carcinomas and only in 9% of the serous tumors of borderline malignancy. No staining was detected in serous cystadenomas or in the normal ovary. In 8 of 30 positively stained serous carcinomas, >50% of the tumor cells expressed MAGE-A4. NY-ESO-1 expression was seen in 19% of the serous carcinomas, whereas serous tumors of borderline malignancy and cystadenomas were negative. A significant inverse correlation was found between MAGE-A4 expression and patient survival (P = 0.016). Multivariate analysis revealed that both tumor stage and MAGE-A4 expression were independent predictors of patient survival (P = 0.022 and P = 0.013, respectively). Conclusions: Cancer-testis antigen expression in ovarian serous neoplasms correlates directly with their degree of malignancy. MAGE-A4 expression, and to a lesser degree NY-ESO-1 expression, is characteristic of the majority of serous carcinomas. Determining the degree of MAGE-A4 expression in these tumors may provide important prognostic information. Finally, MAGE-A4 may represent a novel target for immunotherapy in serous ovarian neoplasms.
引用
收藏
页码:6453 / 6460
页数:8
相关论文
共 50 条
  • [1] Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Ito, Tomohiko
    Oka, Naohiro
    Kakinoki, Ryosuke
    Akagi, Masao
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2022, 66 (03):
  • [2] Expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 Cancer-Testis Antigens in Fetal Testis
    Hudolin, Tvrtko
    Kastelan, Zeljko
    Derezic, Danijel
    Basic-Jukic, Nikolina
    Spagnoli, Giulio Cesare
    Juretic, Antonio
    Jezek, Davor
    ACTA DERMATOVENEROLOGICA CROATICA, 2009, 17 (02) : 103 - 107
  • [3] Expression of cancer testis antigens NY-ESO-1, MAGE-A1 and MAGE-A4 as a prognostic factor in patients with primary cutaneous melanoma
    Katalinic, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 36 - 36
  • [4] Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China
    Chen, Anni
    Qiu, Yuling
    Yen, Ying-Tzu
    Wang, Chun
    Wang, Xiaolu
    Li, Chunhua
    Wei, Zijian
    Li, Lin
    Yu, Lixia
    Liu, Fangcen
    Li, Rutian
    CANCER MEDICINE, 2025, 14 (07):
  • [5] Expression of cancer testis antigens NY-ESO-1, MAGE-A1 and MAGE-A4 as a prognostic factor in patients with primary cutaneous melanoma
    Katalinic, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (03) : E48 - E48
  • [6] Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma
    Errington, J. A.
    Conway, R. M.
    Walsh-Conway, N.
    Browning, J.
    Freyer, C.
    Cebon, J.
    Madigan, M. C.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (03) : 451 - 458
  • [7] Seminal expression of NY-ESO-1 and MAGE-A4 as markers for the testicular cancer
    Satie, Anne-Pascale
    Auger, Jacques
    Chevrier, Cecile
    Le Bon, Cynthia
    Jouannet, Pierre
    Samson, Michel
    Jegou, Bernard
    INTERNATIONAL JOURNAL OF ANDROLOGY, 2009, 32 (06): : 713 - 719
  • [8] Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance
    Yoshida, N
    Abe, H
    Ohkuri, T
    Wakita, D
    Sato, M
    Noguchi, D
    Miyamoto, M
    Morikawa, T
    Kondo, S
    Ikeda, H
    Nishimura, T
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 28 (05) : 1089 - 1098
  • [9] Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Ito, Tomohiko
    Akagi, Masao
    DIAGNOSTICS, 2022, 12 (03)
  • [10] Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck
    Veit, Johannes A.
    Heine, Daniela
    Thierauf, Julia
    Lennerz, Jochen
    Shetty, Subasch
    Schuler, Patrick J.
    Whiteside, Theresa
    Beutner, Dirk
    Meyer, Moritz
    Gruenewald, Inga
    Ritter, Gerd
    Gnjatic, Sacha
    Sikora, Andrew G.
    Hoffmann, Thomas K.
    Laban, Simon
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (07): : 1008 - 1016